Microbot Medical Inc. announced that following the recent positive results of its pivotal GLP Pre-Clinical Study, and to support its anticipated IDE submission to commence its first in human clinical trial, the Company added a US- based Clinical Research Associate (CRA). The CRA will join the already established clinical team in the USA, led by Dr. Juan Diaz-Cartelle, the Company's Chief Medical Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9233 USD | +0.36% | -5.77% | -43.70% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.70% | 13.29M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- MBOT Stock
- News Microbot Medical Inc.
- Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study